Burzynski Research Institute (BZYR) Assets Average (2011 - 2025)
Burzynski Research Institute (BZYR) posted Assets Average of $1798.0 for Q4 2025, up 26.09% sequentially from $1426.0 in Q3 2025, and up 54.4% YoY from $1164.5 in Q4 2024.
Burzynski Research Institute (BZYR) Assets Average (2011 - 2025) Analysis & Trends
Burzynski Research Institute has reported Assets Average for 15 years, with the latest figure at $1798.0 in Q4 2025.
- Quarterly Assets Average rose 54.4% year-over-year to $1798.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was $1798.0 (up 54.4% YoY) and the FY2025 annual result came in at $1578.5, down 25.61% from the prior year.
- Assets Average grew to $1798.0 in Q4 2025 per BZYR's latest filing, from $1426.0 in the prior quarter.
- Over five years, Assets Average peaked at $5700.0 in Q1 2022 and troughed at $780.0 in Q1 2025.
- A 5-year average of $2113.0 and a median of $1601.2 in 2021 frame the typical range for Assets Average.
- The sharpest annual moves came in 2021 and 2022: Assets Average sank 94.09% in 2021, then surged 267.98% in 2022.
- Over 5 years, Assets Average stood at $4289.5 in 2021, then slumped by 59.69% to $1729.0 in 2022, then fell by 18.74% to $1405.0 in 2023, then declined by 17.12% to $1164.5 in 2024, then jumped by 54.4% to $1798.0 in 2025.
- According to Business Quant data, Assets Average over the past three periods registered $1798.0, $1426.0, and $1184.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | 1,798.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | 1,798.00 |
| Aug 31, 2025 | 1,426.00 |
| May 31, 2025 | 1,184.00 |
| Feb 28, 2025 | 780.00 |
| Nov 30, 2024 | 1,164.50 |
| Aug 31, 2024 | 1,306.50 |
| May 31, 2024 | 1,653.50 |
| Feb 29, 2024 | 1,661.50 |
| Nov 30, 2023 | 1,405.00 |
| Aug 31, 2023 | 1,322.50 |
| May 31, 2023 | 1,391.00 |
| Feb 28, 2023 | 1,863.00 |
| Nov 30, 2022 | 1,729.00 |
| Aug 31, 2022 | 3,566.00 |
| May 31, 2022 | 5,063.50 |
| Feb 28, 2022 | 5,700.00 |
| Nov 30, 2021 | 4,289.50 |
| Aug 31, 2021 | 1,924.50 |
| May 31, 2021 | 1,482.50 |
| Feb 28, 2021 | 1,549.00 |